- United States
- /
- Medical Equipment
- /
- NasdaqGS:ALGN
Align Technology (ALGN) Is Down After Earnings Miss and Legal Scrutiny Will Growth Hopes Hold Up?
Reviewed by Simply Wall St
- Earlier this month, Align Technology reported its second quarter 2025 financial results, missing revenue estimates and lowering both third-quarter guidance and full-year growth expectations, which led to the announcement of law firm investigations into alleged securities law violations and possible unlawful business practices by company leadership.
- This heightened scrutiny follows recent patent infringement lawsuits filed by Align against Angelalign Technology, as well as broader industry concerns over economic uncertainty and reduced demand for discretionary dental procedures.
- We'll examine how disappointing earnings and the launch of multiple securities investigations may affect Align Technology's longer-term growth outlook.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Align Technology Investment Narrative Recap
Investors in Align Technology need to believe in the company's ability to reignite global demand for clear aligners and capitalize on new product launches, despite strong competitive headwinds and evolving consumer sentiment. The recent revenue miss and lowered guidance weigh on short-term sentiment, and investigations into potential securities law violations add further pressure, putting both near-term demand recovery and reputational risk in sharper focus. However, these developments do not appear to meaningfully impact the company’s most important long-term growth initiatives at this stage.
The announcement of patent infringement lawsuits against Angelalign Technology is particularly relevant to the competitive pressures highlighted this quarter. Protecting intellectual property is central to Align's brand and ability to maintain pricing power, especially as rivals continue to challenge its market share in key international regions. Legal outcomes in these disputes could shape Align’s ability to defend its market position going forward.
In contrast, investors should be aware of how persistent macroeconomic uncertainty can continue to suppress demand for elective dental procedures, especially if patient traffic...
Read the full narrative on Align Technology (it's free!)
Align Technology's narrative projects $4.5 billion in revenue and $674.9 million in earnings by 2028. This requires 4.6% yearly revenue growth and a $237.3 million increase in earnings from $437.6 million today.
Uncover how Align Technology's forecasts yield a $186.36 fair value, a 25% upside to its current price.
Exploring Other Perspectives
Simply Wall St Community members provided seven fair value estimates for Align Technology ranging from US$110.08 to US$314.01. With competitive risks and patent challenges in focus, opinions can differ widely so explore several viewpoints.
Explore 7 other fair value estimates on Align Technology - why the stock might be worth over 2x more than the current price!
Build Your Own Align Technology Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Align Technology research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Align Technology research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Align Technology's overall financial health at a glance.
Searching For A Fresh Perspective?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:ALGN
Align Technology
Provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.
Flawless balance sheet and fair value.
Similar Companies
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
SLI is share to watch next 5 years

The "Molecular Pencil": Why Beam's Technology is Built to Win
PRME remains a long shot but publication in the New England Journal of Medicine helps.
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
